Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2011 - 2026)
Niagen Bioscience (NAGE) reported Depreciation & Amortization (CF) of $116000.0 for Q1 2026, down 26.58% year-over-year from $158000.0 in Q1 2025, and down 16.55% quarter-over-quarter from $139000.0 in Q4 2025.
Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $116000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $116000.0, down 26.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $570000.0 (down 11.35% YoY), and the FY2025 annual result was $612000.0, down 7.69% from the prior year.
- Depreciation & Amortization (CF) eased to $116000.0 in Q1 2026 per NAGE's latest filing, from $139000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $235000.0 in Q3 2022 and troughed at $116000.0 in Q1 2026.
- A 5-year average of $184117.6 and a median of $177000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) climbed 13.43% in 2023, then decreased 29.61% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $221000.0 in 2022, then retreated by 19.91% to $177000.0 in 2023, then retreated by 14.69% to $151000.0 in 2024, then fell by 7.95% to $139000.0 in 2025, then dropped by 16.55% to $116000.0 in 2026.
- Business Quant data shows NAGE's Depreciation & Amortization (CF) at $116000.0 in Q1 2026, $139000.0 in Q4 2025, and $157000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Niagen Bioscience | 275.31 Mn | 208.77 Mn | 19.98 Mn | 116,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116,000.00 |
| Mar 31, 2026 | 116,000.00 |
| Dec 31, 2025 | 139,000.00 |
| Dec 31, 2025 | 139,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Mar 31, 2025 | 158,000.00 |
| Mar 31, 2025 | 158,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 177,000.00 |
| Dec 31, 2023 | 177,000.00 |